ESG Report 2019

22 Major R&D Pipeline As of December 31, 2019, the Group had a carried out 17 consistency evaluation projects total of 29 generic drugs and new drug in progress. The Group currently has a variety projects under research, including 14 of key research and development products. chemical drugs and 15 biologics, 4 of which The product treatment areas and the were pending approval for production and 2 corresponding stages of research and were in clinical stage, 2 were pending clinical development are as above(Major R&D approval, and 21 were in the preclinical Pipeline). It is expected that these products research stage. In addition, the Group actively will lay a good foundation for the Group's responded to the sustainable development in its future Evaluation for Generic Drugs and operations. Consistency of Quality and Efficacy Product Insulin Aspart Injection Insulin Aspart 30 Injection Liraglutide Injection Insulin Degludec Injection Insulin Degludec/Liraglutide Injection Insulin Aspart 50 Injection Semaglutide Injection GLP-1 Oral Preparation Intelligent Insulin Insulin Degludec/Insulin Aspart WXSH0150 Tenofovir Disoproxil Fumarate Tablets Polyvinyl Alcohol Eye Drops Sodium Hyaluronate Eye Drops Moxifloxacin Eye Drops Stage of Research and Development FIELD ： STAGES ： Diabetes medications Production declaration Rheumatoid arthritis Dry eye syndrome Hepatitis B and AIDS Conjunctivitis Clinical trial Clinical declaration Preclinical Environmental, Social and Governance Report 2019 The United Laboratories International Holdings Limited